- $694.24m
- $733.01m
- $502.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.32% | ||
| Return on Equity | n/a | ||
| Operating Margin | -4.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 203 | 252.48 | 324.24 | 393.41 | 502.73 | 660.09 | 859.11 | 21.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 1st, 2019
- Public Since
- March 13th, 2020
- No. of Shareholders
- 35
- No. of Employees
- 641
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 100,468,979
- Address
- 18000 Studebaker Road, Suite 800, CERRITOS, 90703
- Web
- https://starlingoncology.com
- Phone
- +1 5627353226
- Auditors
- BDO USA, LLP
Latest News for STLN
Upcoming Events for STLN
Q3 2026 Starling Oncology, Inc. Earnings Release
Starling Oncology, Inc. at APG Fall Conference
Q4 2026 Starling Oncology, Inc. Earnings Release
Similar to STLN
ADVANCED BIOMED
NASDAQ Capital Market
IMEI Technology Health
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Amatuhi Holdings
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
FAQ
As of Today at 05:30 UTC, shares in Starling Oncology are trading at $6.91. This share price information is delayed by 15 minutes.
Shares in Starling Oncology last closed at $6.91 and the price had moved by +57.4% over the past 365 days. In terms of relative price strength the Starling Oncology share price has outperformed the S&P500 Index by +38.4% over the past year.
The overall consensus recommendation for Starling Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreStarling Oncology does not currently pay a dividend.
Starling Oncology does not currently pay a dividend.
Starling Oncology does not currently pay a dividend.
To buy shares in Starling Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.91, shares in Starling Oncology had a market capitalisation of $694.24m.
Here are the trading details for Starling Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: STLN
Based on an overall assessment of its quality, value and momentum Starling Oncology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Starling Oncology is $9.40. That is 36.03% above the last closing price of $6.91.
Analysts covering Starling Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$0.16 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Starling Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +99.03%.
As of the last closing price of $6.91, shares in Starling Oncology were trading +49.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Starling Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Starling Oncology's directors